Visiongain has published a new report on Pyrogen Testing Market Report 2021-2031: Forecasts By Product (Kits and Reagents, Services, and Instruments), By Application (Pharmaceutical and Biological Manufacturing, Medical Device Manufacturing, Medical Device Manufacturing, and Other Applications), By Test Type (LAL Tests, In Vitro Tests, Rabbit Tests, TAL Test, Monocyte Activation Test Test (MAT), Recombinant Factor C Assay (rFC), Rabbit Pyrogen Tests (RPT), and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By Distribution Channel (Direct Tender, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Pyrogen Testing market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Pyrogen Testing market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Pyrogen Testing Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Pyrogen Testing market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Rapid Growth in Pharmaceutical and Biotechnology Industries
The burden of chronic and Non-chronic disease is increasing very rapidly around the world, and it is expected to continuously rise over the forecast period. Increasing prevalence of chronic and non-chronic disease is increasing demand for drugs and therapies around the world. Recently, the market has reported a sudden rise in the pharmaceutical and biotechnology industries with increasing demand of drugs along with increasing regulatory approvals for it. Various manufacturers have increased their product development activities for development of new drugs and on the other hand many manufacturers have launched their clinical trials which have helped to fulfil demand and to work as a driver for the market. Rapid growth in pharmaceutical and biotechnology industries is increasing demand of pyrogen testing for quality control of the products due to this reason the factor is working as a driver for the market.

Increasing Therapeutic Advancements in Pharmaceutical and Biotechnology Industries
The burden of chronic and non-chronic disease had guided top leading manufactures to increase their research and development activities with pyrogen testing for quality control of injectable drugs and medical devices. Research and development activities for new technology in pharmaceutical and biotechnology industries are helping to increase adoption of pyrogen testing. Research and development activities with pyrogen testing is improvising treatment options, making great strides, and increasing quality of life for people suffering from life threatening disease. Currently, many of the manufacturers use pyrogen testing for quality control of their product portfolios which is expected to fulfil demand and to work as a driver for the market.

Market Opportunities

Developing Countries Present Significant Opportunities for the Pyrogen Testing Market
Governments, international organisations and regulatory authorities in various developing nations are making huge efforts to transition their healthcare infrastructure from less developed and advanced healthcare infrastructure towards a modern, advanced and developed healthcare infrastructure. Increasing focus on healthcare infrastructure is expected to untapped the potential markets in the developing countries. Developing countries are expected to be the next most growing market in the forecasted period as the manufactures are already started to take various strategic initiatives such as acquisition & merger, product launch, licence acquisition, regulatory approval and others to dominate or increase their market share in the potential in emerging markets. Moreover, key market manufactures are shifting their focus towards untapped potential in emerging markets which is expected to create more new growth opportunities. Due to this reason the factor is creating various opportunities for the pain management therapeutics market.

Competitive Landscape

Top companies (Charles River, Lonza, and Merck KGaA) constitute more than XX% share of the global Pyrogen Testing market. Other companies profiled in the report include: Ellab A/S, GenScript, Hyglos GmbH, Thermo Fisher Scientific Inc., Wako USA, WuXi AppTec, and Associates of Cape Cod, Inc. Some of the key developments are listed below:

● In 2020, Lonza Bioscience has launched PyroCell Monocyte Activation Test System which is a reliable and a sustainable solution for in vitro pyrogen testing. The launch will help the company to expand pyrogen testing and widened revenue generation from a market focused product portfolio.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.